| |
| |
|
| Insider
Information: |
Cox John |
| Relationship: |
|
| City: |
Weston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
44,968 |
|
|
Indirect Shares
|
4,444 |
|
|
| Direct
Value |
$8,433,904 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
49,412 |
|
|
| Total
Value |
$8,433,904 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 401.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biogen Idec Inc |
BIIB |
EVP Pharmaceutical Ope... |
2016-04-01 |
39,045 |
|
0 |
Premium* |
|
|
Repligen Corp |
RGEN |
Director |
2020-03-24 |
923 |
2015-05-21 |
0 |
Premium* |
|
|
Bioverativ Inc. |
BIVV |
Chief Executive Office... |
2018-03-08 |
0 |
2017-02-28 |
0 |
Premium* |
|
|
Sigilon Therapeutics, Inc. |
SGTX |
|
2023-08-11 |
0 |
2020-12-08 |
4,444 |
Premium* |
|
|
Dyne Therapeutics, Inc. |
DYN |
|
2024-03-25 |
5,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| DYN |
Dyne Therapeutics, Inc. |
CEO & President |
• • – |
2024-03-25 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| DYN |
Dyne Therapeutics, Inc. |
See Remarks |
• • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
% |
|
| SGTX |
Sigilon Therapeutics, Inc... |
|
– • – |
2023-08-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(341) |
0 |
0 |
- |
|
| SGTX |
Sigilon Therapeutics, Inc... |
Director |
– • – |
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
4,444 |
4,444 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-24 |
4 |
S |
$96.72 |
$179,706 |
D/D |
(1,858) |
923 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-18 |
4 |
OE |
$12.91 |
$651,603 |
D/D |
26,736 |
29,517 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-18 |
4 |
S |
$95.13 |
$2,547,035 |
D/D |
(26,736) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-04 |
4 |
S |
$93.39 |
$933,900 |
D/D |
(10,000) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-03-04 |
4 |
OE |
$12.91 |
$129,100 |
D/D |
10,000 |
12,781 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2020-02-24 |
4 |
S |
$92.76 |
$413,455 |
D/D |
(4,455) |
2,781 |
0 |
% |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,236 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2018-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,486 |
6,313 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(185,094) |
0 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-23 |
4 |
D |
$104.74 |
$606,864 |
D/D |
(5,794) |
185,094 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-22 |
4 |
D |
$104.30 |
$1,457,384 |
D/D |
(13,973) |
190,888 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-14 |
4 |
D |
$103.52 |
$1,119,983 |
D/D |
(10,819) |
204,861 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,339 |
215,680 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-11 |
4 |
OE |
$9.53 |
$175,171 |
D/D |
18,381 |
199,013 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2018-02-11 |
4 |
D |
$103.05 |
$790,600 |
D/D |
(7,672) |
191,341 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2017-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,206 |
4,827 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2017-03-31 |
4 |
D |
$54.46 |
$458,335 |
D/D |
(8,416) |
180,632 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2017-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
211,679 |
226,979 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Executive Officer |
• • – |
2017-02-28 |
4 |
D |
$43.42 |
$1,748,144 |
D/D |
(37,931) |
189,048 |
0 |
- |
|
| RGEN |
Repligen Corp |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,763 |
3,621 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
• • – |
2016-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,444 |
39,045 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
